The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).
 
MinYuen Teo
No Relationships to Disclose
 
Kenneth Seier
No Relationships to Disclose
 
Irina Ostrovnaya
No Relationships to Disclose
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Brooke Elizabeth Kania
No Relationships to Disclose
 
Meredith Maisie Moran
No Relationships to Disclose
 
Catharine Kline Cipolla
No Relationships to Disclose
 
Mark J. Bluth
No Relationships to Disclose
 
Joshua Chaim
No Relationships to Disclose
 
Hikmat Al-Ahmadie
No Relationships to Disclose
 
David B. Solit
Honoraria - Loxo; Pfizer
Consulting or Advisory Role - Loxo; Pfizer
 
Samuel Funt
Stock and Other Ownership Interests - Kite, a Gilead company
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Potenza Therapeutics; Vesuvius Pharmaceuticals
Honoraria - Regeneron
Consulting or Advisory Role - Advaxis; Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; Chugai Pharma; FSC Pediatrics; Genentech; Jounce Therapeutics; Lilly; MedImmune; Merck; Polaris; Polynoma; Potenza Therapeutics; Sellas Life Sciences; Tizona Therapeutics, Inc.; ZIOPHARM Oncology
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Chugai Pharma; Janssen; Kadmon; Regeneron; Roche
 
Gopa Iyer
No Relationships to Disclose
 
Alexandra Snyder Charen
Consulting or Advisory Role - Driver Group; Third Rock Ventures
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; UpToDate
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Lilly; Merck; Oncogenex; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education